Gut Hormones After Roux-en-Y Gastric Bypass (RYGBP) Plus Gastric Fundus Resection
NCT ID: NCT01341028
Last Updated: 2011-04-25
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
24 participants
INTERVENTIONAL
2007-05-31
2010-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
* Over the last years increasing evidence suggests that the beneficial effects of bariatric operations might be related to the suppression of appetite caused by the release of the anorectic gut hormones such as peptide-YY (PYY) and glucagon-like peptide-1 (GLP-1)by the L cells of the distal gut and the suppression of the orexigenic hormone ghrelin released by the stomach.Obese people have a blunted rise in PYY and GLP-1 after a meal, possibly resulting in impaired satiety and hence greater food intake.
* In the present study the investigators sought to evaluate the effects of the resection of the gastric fundus, the main source of ghrelin production, on the secretion of ghrelin, PYY, GLP-1 and insulin and in addition on glucose levels, appetite and weight loss, in morbidly obese patients undergoing laparoscopic Roux-en-Y gastric bypass.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
GAstric Bypass to Treat obEse Patients With steAdy hYpertension
NCT01784848
Gastric Bypass With Different Lengths of the Bilipancreatic Limb
NCT05334173
Diabetes Remission After RYGBP and RYGBP With Fundus Resection
NCT05854875
Omega Loop Versus Roux-en-Y Gastric Bypass
NCT02139813
L-Cell Activity in Small Intestine as Biliopancreatic Loop in Obese Patients With DM2 Submitted to RYGBP
NCT05446415
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
All human studies were performed according to the principles of the Declaration of Helsinki. The local Research and Ethics Commitee at the University Hospital of Patras approved the study. Written informed consent was obtained from all patients.
All the operations were performed by the same surgeon laparoscopically. The RYGBP procedures were performed creating a small isolated lesser curve-based gastric pouch (20 ± 5 ml) and a 150cm Roux limb. The gastroenteroanastomosis was conducted with a 25 mm circular stapler. The dissection of the fundus of the stomach in the (LRYGBP+FR) group was done with the use of EndoGia No 60.
The subjects were studied before and at 3, 6 and 12 months after the operation. All the patients underwent an oral glucose tolerance test (OGTT) with 75 g glucose, preoperatively. In addition, venous blood was collected after an overnight 12 hour fast and 30, 60 and 120 min after the administration of a 300 kcal mixed meal.The meal was consumed in ten minutes and consisted of 18% protein, 55% carbohydrate and 27% fat (Resource energy drink, Nestle Nutrition, France). Plasma levels of PYY, GLP-1, ghrelin and insulin were determined at every time point of the study. All patients underwent complete clinical evaluation during follow-up including nutritional, behavioral and anthropometric parameters. Visual analogue scales (VAS) were used to measure hunger, nausea, fullness and aversion to food, before and 30, 60 and 120 min after the consumption of the meal. Weight loss evaluation was based on postope¬rative body weight, body mass index (BMI) and % excess weight loss (EWL %).
Insulin resistance was approximated using the homeostatic model assessment for insulin resistance (HOMA IR). The following formula was used in its calculation:
HOMA IR = (fasting glucose \[mmole\] /lt X fasting insulin \[μU/ml\])/22.5). The insulinogenic index, a commonly used indicator of pancreatic β-cell function, was calculated as the ratio of increment of insulin concentrations to that of glucose concentrations at 30 minutes after meal ingestion (Δ \[ins30 - ins0\] / Δ \[Glu30 -Glu0\]).
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
BASIC_SCIENCE
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Roux-en-Y gastric bypass (LRYGBP)
Twelve subjects underwent laparoscopic Roux-en-Y gastric bypass
Roux-en-Y gastric bypass (LRYGBP)
Twelve patients underwent laparoscopic Roux-en-Y gastric bypass
LRYGBP plus gastric fundus resection
Twelve patients underwent laparoscopic Roux-en-Y gastric bypass plus gastric fundus resection
LRYGBP+gastric fundus resection
Twelve patients underwent laparoscopic Roux-en-Y gastric bypass and gastric fundus resection
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Roux-en-Y gastric bypass (LRYGBP)
Twelve patients underwent laparoscopic Roux-en-Y gastric bypass
LRYGBP+gastric fundus resection
Twelve patients underwent laparoscopic Roux-en-Y gastric bypass and gastric fundus resection
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* diabetes mellitus
* substance abuse
* chronic medical or psychiatric illness
* previous gastrointestinal surgery
18 Years
55 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Patras
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Professor of Medicine, University of Patras School of Medicine
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Theodore K Alexandrides
Role: PRINCIPAL_INVESTIGATOR
Professor of Medicine, School of Medicine, University of Patras
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University Hospital of Patras
Rio, Achaia, Greece
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
RYGBPFR001
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.